| 초록 |
Although heparin can regulate angiogenesis, tumor growth, its clinical application, as well as that of low-molecular weight heparin(LMWH) which is used carrier, for treating cancer are limited because of heparin’s anticoagulant activity and risk of hemorrhages. These carriers need to be biocompatible, highly soluble, stable, capable of loading large amount of anticancer drugs and able to conjugate with the targeting moleculars. Also Docetaxel is important chemotherapeutic drug widely used today for treatment of various types of cancer. Docetaxel is known to exert its therapeutic effect. However, the clinical usefulness of this drug is particularly hampered by their poor solubility. In this study Heparin-docetaxel conjugates were designed a self assembled nanoparticles for using LMWH as a hydrophilic segment and Docetaxel as a hydrophobic segment. The chemical bonding of the conjugates was characterized by 1H-NMR, FT-IR, UV/Vis spectroscopy, dynamic light scattering(DLS). |
